Combating Counterfeit Pharmaceuticals Act of 2025
- Bill Number
- S. 3134
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- International Affairs
- Status
- Introduced
- Latest Action
- 2025-11-06: Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
- Last Updated
- 2026-04-01T19:28:19Z
AI-Generated Summary
Purpose of the Legislation
The Combating Counterfeit Pharmaceuticals Act of 2025 aims to expand the Fentanyl Sanctions Act (a law focused on penalizing foreign entities involved in fentanyl trafficking) to address the broader trafficking of counterfeit drugs (fake versions of legitimate medicines), copy-cat ingredients (imitation components of approved drugs that are substandard or improperly made), and active pharmaceutical ingredients used in illicit drugs. It seeks to strengthen U.S. sanctions and intelligence efforts against these threats to public health and national security.
Key Provisions
- New Definitions (Section 2):
- Defines "copy-cat ingredient" as a drug component designed to imitate an approved or licensed prescription drug but made differently (e.g., via altered manufacturing processes) or with lower purity/quality.
- Defines "counterfeit drug" by referencing the existing Federal Food, Drug, and Cosmetic Act, which covers fake or mislabeled drugs.
- Broadens terms like "illicit drug" to replace "opioid" throughout, extending coverage to non-opioid illicit substances.
- Updates sanctions applicability to include trafficking in counterfeit drugs and copy-cat ingredients.
- Intelligence and Delegation Updates (Section 3):
- Allows the Director of National Intelligence (or a designee) to handle identification of foreign drug traffickers and provide briefings on sanctions implementation.
- Establishes a simplified program for using intelligence resources to combat illicit drug trafficking, removing prior consultation requirements with other agencies and focusing on broader illicit drugs rather than just opioids.
- Waivers for Medication Access (Section 4):
- Permits waivers from sanctions if they would restrict access to prescription medications on the U.S. drug shortage list (maintained by the Department of Health and Human Services), ensuring critical medicines remain available.
- Technical Amendments (Section 5):
- Replaces opioid-specific language with "illicit drugs" across the Fentanyl Sanctions Act and related laws (e.g., Foreign Assistance Act).
- Updates references to traffickers, trafficking, and reports to cover foreign illicit drug activities more generally.
Significant Changes to Existing Law
- Expands the scope of the Fentanyl Sanctions Act from targeting only opioid (especially fentanyl) trafficking to all illicit drugs, including counterfeits and copy-cats, which were not explicitly covered before.
- Introduces delegation authority for the Director of National Intelligence, streamlining operations without needing direct involvement in every task.
- Simplifies the intelligence program's structure by eliminating certain subsections and consultations, making it more efficient.
- Ties sanctions waivers explicitly to the official drug shortage list, providing clearer criteria than the previous vague reference to "medications."
- Makes conforming changes to terminology in multiple laws, ensuring consistency and avoiding narrow interpretations limited to opioids.
Potential Impacts
- On Government Agencies: Enhances tools for agencies like the Office of the Director of National Intelligence, Department of State, and Treasury to identify and sanction foreign traffickers more broadly, potentially increasing workload in monitoring counterfeit drug networks but improving coordination through delegation.
- On Citizens: Improves public health by targeting dangerous fake drugs that could enter the U.S. supply chain, reducing risks from substandard or contaminated medicines; waivers protect access to scarce legitimate drugs during shortages.
- On International Relations: Could strain ties with countries (e.g., those in Asia or Latin America) harboring trafficking networks, as sanctions may target foreign entities, businesses, or governments; may encourage international cooperation on drug enforcement but risk retaliatory measures.
Main Stakeholders Affected
- U.S. Government Agencies: Intelligence community (e.g., Director of National Intelligence), sanctions enforcers (e.g., Treasury's Office of Foreign Assets Control), and health regulators (e.g., FDA, HHS) will implement expanded monitoring and waivers.
- Foreign Entities: Drug traffickers, manufacturers of counterfeit/copy-cat drugs, and pharmaceutical suppliers in countries like China or Mexico, who may face new U.S. sanctions, asset freezes, or travel bans.
- Pharmaceutical Industry: Legitimate drug makers and importers benefit from protections against counterfeits but must navigate updated shortage-related waivers.
- U.S. Citizens and Public Health: Consumers, especially those relying on prescription drugs, gain safeguards against illicit fakes; vulnerable populations (e.g., in opioid or addiction crises) may see indirect benefits from broader anti-trafficking efforts.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens the sanctions framework under the Fentanyl Sanctions Act without creating new penalties, relying on existing mechanisms like asset blocking; ensures compliance with drug safety laws (e.g., Federal Food, Drug, and Cosmetic Act) by integrating shortage waivers, potentially reducing legal challenges to sanctions.
- Constitutional: Aligns with Congress's foreign affairs powers (e.g., regulating commerce and imposing sanctions), avoiding direct domestic restrictions; delegation to designees upholds executive flexibility without overreach.
- Political: Signals a bipartisan push (introduced by Senators Cotton and Ricketts) to combat the evolving drug crisis beyond opioids, amid rising concerns over counterfeit fentanyl-laced pills; may influence future trade or diplomatic negotiations by pressuring source countries, but could face criticism for broadening sanctions without new funding for enforcement.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-11-06: Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
- 2025-11-06: Introduced in Senate
Bill Versions
- Combating Counterfeit Pharmaceuticals Act of 2025 — issued 2025-11-06 — PDF (6 pages)